Subgroup analysis revealed that following 1 month of treatment with Vericiguat combined with the “new quadruple” drug, patients with dilated cardiomyopathy and heart failure demonstrated significant improvements in left ventricular cavity size and scores of cardiac function indicators (including LAD, LVESD, LVEDD, LVEF), as well as NT-proBNP levels and MLHFQ scores when compared to pre-treatment values (<0.01). The gene discussed is NPPB; the disease is heart failure.